ASCO 2023 | CAR-NK for B-cell malignancies: the ELiPSE-1 study of CNTY-101
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the ongoing Phase I ELiPSE-1 study (NCT05336409) investigating CNTY-101, a CD19-directed CAR-NK cell therapy, for patients with CD19-positive relapsed/refractory (R/R) B-cell malignancies. Dr Patel shares information about the therapy and the inclusion criteria for the trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So ELiPSE-1 is an ongoing study of a novel CAR natural killer cell. So this is named CNTY-101 and 101 is engineered with a number of different alterations to try to cloak the CAR-NK cell from the immune system. So it includes several different genomic edits that are distinct from other CAR-NKs that have been studied. It’s CD19-directed, so the study ELiPSE-1 is enrolling patients with relapsed/refractory B-cell lymphomas, patients who have had prior CD19-directed therapy, either CAR-T cell therapy or other therapies are permitted on the trial as long as they continue to express CD19...
So ELiPSE-1 is an ongoing study of a novel CAR natural killer cell. So this is named CNTY-101 and 101 is engineered with a number of different alterations to try to cloak the CAR-NK cell from the immune system. So it includes several different genomic edits that are distinct from other CAR-NKs that have been studied. It’s CD19-directed, so the study ELiPSE-1 is enrolling patients with relapsed/refractory B-cell lymphomas, patients who have had prior CD19-directed therapy, either CAR-T cell therapy or other therapies are permitted on the trial as long as they continue to express CD19. So the study is currently ongoing and we’re looking forward to learning from the experiences of the trial and hopefully we’ll have data to report at an upcoming conference.
Read more...
Disclosures
Consultant or advisory role: Abbvie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Celgene, Epizyme, Genentech/Roche, Kite, Loxo Oncology, MEI Pharma, Morphosys, Pharmacyclics/Janssen, TG Therapeutics, Trillium Therapeutics/Pfizer, Xencor
Research funding: Adaptive Biotechnologies, Aptevo Therapeutics, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Celgene, Curis, Inc, Epizyme, Fate Therapeutics, Genentech/Roche, Kite, Loxo Oncology, MEI Pharma, Nurix, Pharmacyclics/Janssen, Sunesis, Pharmaceuticals, Trillium Therapeutics/Pfizer, Velos Bio, Xencor
